Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

Faculty Opinions recommendation of Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726972508.793526277 ◽

2016 ◽

Author(s):

Toshihiro Horii ◽

Nirianne Palacpac

Keyword(s):

Combination Treatment ◽

Controlled Trial ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial

The Lancet Global Health ◽

10.1016/s2214-109x(16)30236-4 ◽

2017 ◽

Vol 5 (1) ◽

pp. e60-e68 ◽

Cited By ~ 9

Author(s):

Hypolite Muhindo Mavoko ◽

Carolyn Nabasumba ◽

Raquel Inocêncio da Luz ◽

Halidou Tinto ◽

Umberto D'Alessandro ◽

...

Keyword(s):

Combination Treatment ◽

Controlled Trial ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Faculty Opinions recommendation of Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736675072.793566801 ◽

2019 ◽

Author(s):

Pedro Legua Leiva

Keyword(s):

Single Dose ◽

Multiple Dose ◽

Strongyloides Stercoralis ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Superiority Trial ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)

Modern Rheumatology ◽

10.1080/14397595.2018.1538004 ◽

2019 ◽

Vol 30 (1) ◽

pp. 132-140 ◽

Cited By ~ 5

Author(s):

Mitsumasa Kishimoto ◽

Atsuo Taniguchi ◽

Ayako Fujishige ◽

Shuhei Kaneko ◽

Sibylle Haemmerle ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Efficacy and safety of JR-051, a biosimilar of agalsidase beta, in patients with Fabry disease; results of a multicenter, open-label phase 3 study in Japan

Molecular Genetics and Metabolism ◽

10.1016/j.ymgme.2017.12.201 ◽

2018 ◽

Vol 123 (2) ◽

pp. S79

Author(s):

Minako Kobayashi ◽

Tatsuyoshi Yamamoto ◽

Mariko Yamaoka ◽

Teiji Tomio

Keyword(s):

Fabry Disease ◽

Agalsidase Beta ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30723-8 ◽

2019 ◽

Vol 393 (10189) ◽

pp. 2404-2415 ◽

Cited By ~ 233

Author(s):

Brian I Rini ◽

Thomas Powles ◽

Michael B Atkins ◽

Bernard Escudier ◽

David F McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30339-x ◽

2017 ◽

Vol 18 (7) ◽

pp. 874-886 ◽

Cited By ~ 216

Author(s):

Alice T Shaw ◽

Tae Min Kim ◽

Lucio Crinò ◽

Cesare Gridelli ◽

Katsuyuki Kiura ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

Journal of Gastroenterology ◽

10.1007/s00535-018-1503-x ◽

2018 ◽

Vol 54 (1) ◽

pp. 87-95 ◽

Cited By ~ 25

Author(s):

Tetsuo Takehara ◽

Naoya Sakamoto ◽

Shuhei Nishiguchi ◽

Fusao Ikeda ◽

Tomohide Tatsumi ◽

...

Keyword(s):

Japanese Patients ◽

Decompensated Cirrhosis ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Abstract OT1-04-04: EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy

10.1158/1538-7445.sabcs19-ot1-04-04 ◽

2020 ◽

Author(s):

Philippe Aftimos ◽

Aditya Bardia ◽

Virginia G Kaklamani ◽

Janice Lu ◽

Teeru Bihani ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Inhibitor Therapy ◽

Advanced Breast ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽